

## SUPPLEMENTAL MATERIALS

### The Roles of Insulin Resistance, Hyperinsulinemia, and LH in Peripubertal Obesity-Associated Hyperandrogenemia

Christine M. Burt Solorzano, Karen L. Knudsen, Amy D. Anderson, Eleanor G. Hutchens, Jessica S. Collins, James T. Patrie, John C. Marshall, Christopher R. McCartney

<b>Table of Contents</b>	<b>Pages</b>
Hormone assays .....	2
Supplemental Table 1. Effect of different methods for determining insulin sensitivity index on primary analysis .....	3
Supplemental Table 2. Effect of different methods for determining periprandial insulin levels (for use in the estimated 24-hour insulin calculation) on primary analysis .....	4
Supplemental Table 3. Steroids before and after clamp (subject-level data) .....	5
Supplemental Figure 1. Acute steroid changes with the insulin clamp .....	6

## Hormone Assays

Characteristics of the total testosterone, SHBG, LH, and insulin assays are described in the main text.

FSH, insulin-like growth factor 1 (IGF-1), dehydroepiandrosterone sulfate, and growth hormone were measured by chemiluminescence (Immulin 2000, Siemens, Los Angeles, CA; sensitivity 0.1 IU/L, 25 ng/mL, 7 µg/dL, 0.01 ng/mL; intra-assay CVs 2.5-4.8%; inter-assay CVs 4.4-7.9%).

Estradiol, progesterone, androstenedione, and 17-hydroxyprogesterone were measured by radioimmunoassay (Siemens; sensitivities 10 pg/mL, 0.1 ng/mL, 0.1 ng/mL, and 10 ng/dL; intra-assay CVs 4.3-6.1%; inter-assay CVs 7.1-8.1%).

DHEA was measured by ELISA (ALPCO, Salem, NH; sensitivity 0.4 ng/mL; intra-assay CV 5.7%; inter-assay CV 8.0%).

Glucose levels during insulin clamp were measured by glucose oxidase method via the YSI Life Sciences 2300 glucose analyzer (Yellow Springs Instruments, Yellow Springs, OH; intra-assay and inter-assay precision <2%, limit of detection = 1 mg/dL).

Hemoglobin A1c was measured by high-performance liquid chromatography (Tosoh G7 HPLC Analyzer, Tosoh Bioscience, Inc., South San Francisco, CA; intra-assay precision 1.5% at HbA1c 7-8%; inter-assay precision 3%).

To convert metric units to SI units: 17-hydroxyprogesterone (ng/dL) x 0.030257 (pmol/L); androstenedione (ng/mL) x 3.4916 (pmol/L); dehydroepiandrosterone (ng/mL) x 3.4674 (pmol/L); dehydroepiandrosterone sulfate (µg/dL) x 27.174 (nmol/L); estradiol (pg/mL) x 3.6711 (pmol/L); glucose (mg/dL) x 0.0555 (mmol/L); growth hormone (ng/mL) x 1 (µg/L); insulin (µIU/mL) x 7.1750 (pmol/L); IGF-1 (ng/mL) x 0.1307 (nmol/L); progesterone (ng/mL) x 3.1797 (pmol/L); testosterone, total (ng/mL) x 3.4674 (pmol/L); testosterone, free (pg/mL) x 3.4674 (pmol/L).

**Supplemental Table 1. Effect of different methods for determining insulin sensitivity index (ISI) on primary analysis.** Our *a priori* primary analysis: Partial Spearman rank (nonparametric) correlation to examine the relationship between morning free T (dependent variable) and insulin sensitivity index (independent variable), controlling for estimated 24-hour LH and Tanner stage (covariates). **Panel A:** Average ISI (mean  $\pm$  SD) according to method used. **Panel B:** Correlations between ISI and testosterone (T)—while simultaneously correcting for differences in estimated 24-hour LH and Tanner stage—when using different methods for correcting ISI for subject size.

**A**

Subject size variable used for correcting ISI	ISI (mean $\pm$ SD)
Total mass (kg)	2.23 $\pm$ 1.09
Fat free mass (kg)	3.57 $\pm$ 1.62
Body surface area (m <sup>2</sup> ) <sup>a</sup>	0.94 $\pm$ 0.43

**B**

ISI using the following variable to correct for subject size		Free T (RIA)		Free T (LC-MS/MS)		Total T (RIA)		Total T (LC-MS/MS)	
		r <sub>s</sub>	p	r <sub>s</sub>	p	r <sub>s</sub>	p	r <sub>s</sub>	p
		Total mass (kg)	0.68	0.046	0.78	0.023	0.65	0.060	0.74
Fat free mass (kg)	0.62	0.072	0.7	0.054	0.63	0.064	0.73	0.040	
Body surface area (m <sup>2</sup> ) <sup>a</sup>	0.70	0.035	0.79	0.019	0.70	0.034	0.80	0.017	

Footnote: <sup>a</sup> Body surface area =  $\sqrt{(\text{height [cm]} * \text{weight [kg]}/3600)}$ .

**Supplemental Table 2. Effect of different methods for determining periprandial insulin levels (for use in the estimated 24-hour insulin calculation) on primary analysis.** Our *a priori* primary analysis: Partial Spearman rank (nonparametric) correlation to examine the relationship between morning free T (dependent variable) and insulin sensitivity index (independent variable), controlling for estimated 24-hour LH and Tanner stage (covariates). **Panel A:** Average periprandial insulin levels (mean ± SD) according to method used. **Panel B:** Correlations between estimated 24-hour insulin and testosterone (T)—while simultaneously correcting for differences in estimated 24-hour LH and Tanner stage—when using different methods for determining periprandial insulin levels (for use in the estimated 24-hour insulin calculation).

**A**

Method of determining periprandial insulin concentration	Resulting periprandial insulin concentration (mean ± SD)
Mean insulin 1800-2100 h	76.1 ± 34.9
Mean insulin 1800-2200 h	80.0 ± 38.8
Mean insulin 1800-2300 h	75.4 ± 36.8
Mean insulin 1900-2200 h	96.2 ± 49.1
Mean insulin 1900-2300 h	86.5 ± 44.4


**B**

		Free T (RIA)		Free T (LC-MS/MS)		Total T (RIA)		Total T (LC-MS/MS)	
		$r_s$	p	$r_s$	p	$r_s$	p	$r_s$	p
<b>Average 24-hour insulin, calculated using the following periprandial insulin concentration</b>	Mean insulin 1800-2100 h	0.47	0.20	0.36	0.38	0.49	0.18	0.42	0.29
	Mean insulin 1800-2200 h	0.52	0.18	0.43	0.34	0.53	0.18	0.50	0.25
	Mean insulin 1800-2300 h	0.51	0.19	0.43	0.34	0.52	0.18	0.50	0.25
	Mean insulin 1900-2200 h	0.51	0.19	0.43	0.34	0.52	0.18	0.50	0.25
	Mean insulin 1900-2300 h	0.54	0.17	0.49	0.27	0.57	0.14	0.58	0.18

**Supplemental Table 3. Steroid changes with insulin clamp**

	Summary data			Subject number										
	Mean	SD	Median	1	2	3	4	5	6	7	8	9	10	11
0900 h progesterone (ng/mL)	0.36	0.18	0.38	0.28	0.24	0.38	0.41	0.47	0.18	0.71	0.38	0.16	0.20	0.59
1100 h progesterone (ng/mL)	0.37	0.15	0.32	0.31	0.57	0.22	0.32	0.39	0.22	0.58	0.50	0.29	0.19	0.53
0900 h 17-OHP (ng/dL)	89.4	43.0	76.9	55.6	76.9	65.2	116.6	79.0	51.4	179.3	38.5	74.2	99.3	147.1
1100 h 17-OHP (ng/dL)	101.9	38.4	96.4	58.7	169.0	68.3	96.4	113.1	58.3	160.6	70.6	95.4	102.6	128.3
0900 h DHEA (ng/mL)	8.99	11.24	4.37	2.87	4.37	3.99	14.23	3.70	2.97	3.90	11.01	5.36	5.40	41.10
1100 h DHEA (ng/mL)	8.83	7.55	7.30	1.51	7.94	3.48	11.12	7.90	5.14	1.70	16.45	6.98	7.30	27.60
0900 h androstenedione (ng/mL)	2.08	1.42	1.61	1.49	0.83	0.65	3.00	1.61	0.75	5.32	1.30	2.53	1.90	3.49
1100 h androstenedione (ng/mL)	2.10	1.42	2.13	1.31	1.08	0.42	2.30	3.49	0.74	5.35	2.13	2.73	1.24	2.33
0900 h total T (ng/dL)	39.6	27.7	33.1	33.7	10.0	10.0	68.6	33.7	18.4	102.0	33.1	32.8	30.8	62.2
1100 h total T (ng/dL)	35.1	25.7	29.2	29.2	10.0	10.0	63.8	28.7	10.0	91.9	24.6	32.3	30.0	56.0
0900 h estradiol (pg/mL)	24.6	9.2	24.6	24.6	20.7	15.8	39.4	25.4	23.0	32.0	31.8	5.1	21.8	30.9
1100 h estradiol (pg/mL)	19.3	6.5	21.0	16.4	15.4	9.4	28.2	21.2	14.2	28.7	21.3	11.5	21.0	25.3

Abbreviations: 17OHP, 17-hydroxyprogesterone; DHEA, dehydroepiandrosterone; T, testosterone.



**Supplemental Figure 1. Acute steroid changes with the hyperinsulinemic-euglycemic clamp.** In each panel, the data represent the change in hormone concentration from 0900 h (at start of the hyperinsulinemic-euglycemic clamp) to 1100 h (at the end of the hyperinsulinemic-euglycemic clamp). Circles represent data from individual subjects. These data are also summarized using box-and-whisker plots, which show median (line inside the box); mean (open square); 25th and 75th percentiles (bottom and top of box); minimum and maximum (bottom and top whiskers). P values relate to changes from 0900 h to 1100 h.